 SAN DIEGO and CALGARY, Alberta , May 26, 2020 CNW -- Oncolytics Biotech Inc. ONCY ONC.TO, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster ePoster with clinical data from the Companys AWARE-1 window-of-opportunity breast cancer study. The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment TME and the potential of a predictive biomarker T cell clonality to identify patients with breast cancer most likely to respond to pelareorep. The ePoster was published on May 23, 2020 , and presented over the weekend, as part of the European Society for Medical Oncology Breast Cancer Virtual Meeting. 